M. Goldstein from Cantor Fitzgerald is a ball buster, and seems to have a personal issue with GALE. That guy Jason made a good point that Neuvax is ahead of the curve on this type of vaccine, and big Pharma might be scrambling to get into the fold.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.